eligibility_summary
Adults (≥18) scheduled for CAR T therapy. Exclude those refusing consent, prior CAR‑T, active or high-risk bleeding or intracranial bleeding history, primary CNS lymphoma, MRI-incompatible implanted devices (e.g., pacemaker), neurodegenerative disease (PD/AD), prior or evolving neurologic pathology, and pregnant or breastfeeding women.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05643092 is an observational biomarker/imaging study in adults receiving CAR T‑cell therapy for hematologic malignancies to investigate immune effector cell–associated neurotoxicity syndrome (ICANS). No therapeutic drugs are tested. Assessments: cerebrospinal fluid catecholamines (dopamine, norepinephrine, epinephrine) and multimodal brain MRI. Background therapy: CAR T cells (genetically engineered T‑cell adoptive cell therapy) that kill tumor cells via CAR‑mediated antigen recognition and cytotoxic immune activation, which can trigger ICANS. Targeted cells/pathways: immune effector T cells from CAR therapy and central catecholaminergic neurotransmission pathways, with imaging correlates of CNS dysfunction. Aim: identify biomarkers and imaging signatures to aid ICANS detection and prevention.